Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although thrombosis is considered the cardinal feature of the antiphospholipid syndrome, chronic vascular lesions are common, particularly in patients with life-threatening complications. In patients who require transplantation, vascular lesions often recur. The molecular pathways involved in the vasculopathy of the antiphospholipid syndrome are unknown, and adequate therapies are lacking. METHODS: We used double immunostaining to evaluate pathway activation in the mammalian target of rapamycin complex (mTORC) and the nature of cell proliferation in the vessels of patients with primary or secondary antiphospholipid syndrome nephropathy. We also evaluated autopsy specimens from persons who had catastrophic antiphospholipid syndrome. The molecular pathways through which antiphospholipid antibodies modulate the mTORC pathway were evaluated in vitro, and potential pharmacologic inhibitors were also tested in vitro. Finally, we studied the effect of sirolimus in kidney-transplant recipients with the antiphospholipid syndrome. RESULTS: The vascular endothelium of proliferating intrarenal vessels from patients with antiphospholipid syndrome nephropathy showed indications of activation of the mTORC pathway. In cultured vascular endothelial cells, IgG antibodies from patients with the antiphospholipid syndrome stimulated mTORC through the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. Patients with antiphospholipid syndrome nephropathy who required transplantation and were receiving sirolimus had no recurrence of vascular lesions and had decreased vascular proliferation on biopsy as compared with patients with antiphospholipid antibodies who were not receiving sirolimus. Among 10 patients treated with sirolimus, 7 (70%) had a functioning renal allograft 144 months after transplantation versus 3 of 27 untreated patients (11%). Activation of mTORC was also found in the vessels of autopsy specimens from patients with catastrophic antiphospholipid syndrome. CONCLUSIONS: Our results suggest that the mTORC pathway is involved in the vascular lesions associated with the antiphospholipid syndrome. (Funded by INSERM and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oxidative stress and subsequent mTOR activation occurs in various rheumatic diseases257–259.”
From The role of mitochondria in rheumatic diseases (2022) · cites this paper as [257]
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Levine, J. S., Branch, D. W., & Rauch, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmra002974 · Cited by 1,543
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Eisen, H. J., Tuzcu, E. M., Dorent, R., Kobashigawa, J., Mancini, D., Valantine-von Kaeppler, H. A., Starling, R. C., Sørensen, K., Hummel, M., Lind, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022171 · Cited by 1,198
Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF
Ferns, G. A. A., Raines, E. W., Sprugel, K. H., Motani, A. S., Reidy, M. A., & Ross, R. (1991) · Science · doi:10.1126/science.1653454 · Cited by 1,065
Sousa, J. E., Costa, M. A., Abizaid, A. C., Rensing, B. J., Abizaid, A. S., Tanajura, L. F., Kozuma, K., Van Langenhove, G., Sousa, A. G. M. R., Falotico, R., et al. (2001) · Circulation · doi:10.1161/hc4201.098056 · Cited by 672
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Serra, A. L., Poster, D., Kistler, A. D., Krauer, F., Raina, S., Young, J., Rentsch, K. M., Spanaus, K. S., Senn, O., Kristanto, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907419 · Cited by 571
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547
Research works printed but not linked: 1
- Alarcon-Segovia D, 1989, J Rheumatol, 16, 762
Cited by
Items 201–300 of 365
Physiopathologie de l’artérite à cellules géantes : de l’inflammation au remodelage vasculaire
Régent, A., Ly, K. H., & Mouthon, L. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.07.031 · Cited by 9
Mittal, N., Abohelwa, M., Rahman, M. R., & Shurmur, S. W. (2022) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytac199 · Cited by 9
“Typical clinical findings observed are acute respiratory failure, hypotension, valve lesions, acute kidney injury, transaminitis, and livedo reticularis.(6,7) The classification criteria for CAPS include four main components: three or more organs involved, the rapid development of manifestations within a week, histopa…”
BackgroundImmune modulation for autoimmune disorders: evolution of therapeutics
Liebman, H. A. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.04.008 · Cited by 10
Immune complexes suppressed autophagy in glomerular endothelial cells
Wang, L., & Law, H. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.02.013 · Cited by 9
Complement in antiphospholipid syndrome, time to target?
Dragon‐Durey, M., Hamidi, H., & Darnige, L. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102628 · Cited by 8
Self-citation2025 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus
Zhao, J., Zhang, S., Wang, Q., Tian, X., Chen, Y., Li, M., & Zeng, X. (2025) · Rheumatology and Immunology Research · doi:10.1515/rir-2025-0017 · Cited by 10
“[108] Question 6.2: How to use biologics in the treatment of SLE?”
InfluentialTaghavi, M., Jacobs, L., Demulder, A., Jabrane, A., Mesquita, M. D. C. F., Defawe, C., Laureys, M., Dernier, Y., Pozdzik, A., Collart, F., et al. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae308 · Cited by 8
“Its pathophysiology involves the activation of the mammalian target of rapamycin pathway [45 ].”
BackgroundGenetic and genomic associations in antiphospholipid syndrome: A systematic review
Zouein, J., Naim, N., Spencer, D. M., & Ortel, T. L. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103712 · Cited by 9
Solé, C., Royo, M., Sandoval, S., Moliné, T., & Cortés-Hernández, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411607 · Cited by 9
“of APS vasculopathy, wit mTOR inhibitors able to reduce vascular proliferation in APS nephropathy [35,39].”
BackgroundFutami, S., Arai, T., Hirose, M., Sugimoto, C., Ikegami, N., Akira, M., Kasai, T., Kitaichi, M., Hayashi, S., & Inoue, Y. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0933-0 · Cited by 8
Syndrome catastrophique des antiphospholipides (CAPS) : revue 2016
Costedoat-Chalumeau, N., Coutte, L., Guern, V. L., Morel, N., Leroux, G., Paule, R., Mouthon, L., & Pietté, J. C. (2016) · La Presse Médicale · doi:10.1016/j.lpm.2016.07.023 · Cited by 8
Karsulovic, C., López, M. N., Tempio, F., Guerrero, J., & Annelise Goecke, S. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108539 · Cited by 9
Antiphospholipid Syndrome in Renal Allograft Recipients—A Long-Term Multicenter Analysis
Furmańczyk-Zawiska, A., Bułło‐Piontecka, B., Komorniczak, M., Dębska-Ślizień, A. M., Augustyniak‐Bartosik, H., & Durlik, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020667 · Cited by 7
“Recently, several studies have supported knowledge in the field of APSN, indicating that inhibition of mTOR complex is promising in recipients with APS [7,24,25].”
BackgroundThe mTOR pathway in the antiphospholipid syndrome
Ji, L., Zhang, Z., & Perl, A. (2023) · Medical Review · doi:10.1515/mr-2023-0033 · Cited by 7
“The favorable therapeutic effect of mTOR1 pathway inhibition by using rapamycin in APS related microangiopathy had been reported in the retrospective study and case reports [4, 6, 7].”
BackgroundZhao, Y., Qi, W., Huang, C. L., Zhou, Y., Wang, Q., Tian, X., Li, M., Zhao, Y., Zeng, X., & Zhao, J. (2023) · Rheumatology and Therapy · doi:10.1007/s40744-023-00610-9 · Cited by 7
“Antibodies from patients with APS stimulate the mammalian target of rapamycin complex (mTORC) in endothelial cells, which is involved in the pathogenesis of microvascular manifestations [27].”
BackgroundT cell involvement in antiphospholipid syndrome
Tektonidou, M. G., Vlachogiannis, N. I., & Sfikakis, P. P. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110218 · Cited by 7
Lee, J. S., Kim, H., Lee, E. B., Song, Y. W., & Park, J. K. (2016) · Modern Rheumatology · doi:10.1080/14397595.2016.1218596 · Cited by 7
“Strikingly, mTOR inhibitor prevents the allograft vasculopathy, which usually progresses despite adequate anticoagulation, in patients with APS undergoing a renal transplantation [18,20].”
BackgroundHematologic parameters in coronavirus infection (COVID-19) and their clinical implications
Waleed, R. M., Sehar, I., Iftikhar, W., & Khan, H. S. (2020) · Discoveries · doi:10.15190/d.2020.14 · Cited by 7
Immunotherapeutic strategies in antiphospholipid syndrome
Hoi, A. Y.-B., Ross, L., Day, J., & Buchanan, R. R. C. (2016) · Internal Medicine Journal · doi:10.1111/imj.13245 · Cited by 7
Barilaro, G., Espinosa, G., & Cervera, R. (2021) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2021.03.012 · Cited by 7
Immune cell signaling in autoimmune diseases
Tsokos, G. C., & Rose, N. R. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.05.015 · Cited by 7
Antiphospholipid Syndrome and Kidney Involvement: New Insights
Martínez-Flores, J. A., Serrano, M., Morales, J. M., & Serrano, A. (2016) · Antibodies · doi:10.3390/antib5030017 · Cited by 9
“It has been recently described that the mTORC pathway is involved in vascular lesions associated with the APS [101].”
BackgroundFreed, J. A., & Bauer, K. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00014-5 · Cited by 6
A Simplified Understanding of the Black Swan: Anti-phospholipid Antibody Syndrome
Vaidya, B., Nakarmi, S., Joshi, R., & Baral, R. (2019) · Journal of Nepal Medical Association · doi:10.31729/jnma.4226 · Cited by 8
Activation of the mTOR dependent signaling pathway underlies ketamine‐induced uropathy
Lin, C., Yang, A., & Lin, A. T. (2017) · Neurourology and Urodynamics · doi:10.1002/nau.23234 · Cited by 6
Lackner, K. J., & Müller‐Calleja, N. (2018) · Hämostaseologie · doi:10.1055/s-0038-1675355 · Cited by 6
D’Cruz, D. P., Knight, J. S., Sammaritano, L. R., Salmon, J. E., Cervera, R., & Khamashta, M. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-23488-0_14 · Cited by 6
The role of endothelial cells in autoimmune rheumatic disease
Kanitkar, M., & Denton, C. P. (2023) · Current Opinion in Physiology · doi:10.1016/j.cophys.2023.100732 · Cited by 5
“Similarly, in SLE [49] and APS [49,50], rapamycin indirectly targets ECs with effector modulation of T cells, plasma cells and ICs.”
BackgroundHoxha, A., Prete, D. D., Condonato, I., Martino, F. K., Lovisotto, M., Nalesso, F., & Simioni, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103326 · Cited by 5
“Research by Canaud et al. [26] indicates that 70% of patients on mTOR inhibition had a functioning allograft a decade post-transplant compared to just 11% of untreated patients.”
InfluentialNon-communicable chronic diseases: The role of neonatal characteristics
Mauro, A. D., Laforgia, N., Cintoli, A. N., Mincarone, G., Tafuri, S., & Baldassarre, M. E. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.07.103 · Cited by 5
Dar, S., Koirala, S., Khan, A., Bellary, M. D., Patel, A. V., Mathew, B., Singh, R., Baigam, N., Razzaq, W., Abdin, Z. U., et al. (2023) · Cureus · doi:10.7759/cureus.43725 · Cited by 6
“At 144 months post-transplantation, seven of 10 (70%) aPL nephropathy patients treated with rapamycin had a functioning allograft in comparison with only three of 27 (11%) patients who were not treated with rapamycin [255].”
ResultBucci, T., Merashli, M., Pignatelli, P., Pastori, D., Alves, J. D., Lip, G. Y. H., & Ames, P. R. J. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103657 · Cited by 5
Liu, X., Mao, Z., Yuan, M., Li, L., Tan, Y. C. R. S., Qu, Z., Chen, M., & Yu, F. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-000896 · Cited by 5
Jabrane, M., Ez-Zahraoui, M. R., Hajji, I., Fadili, W., Moutaouakil, A., & Laouad, I. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2016.07.455 · Cited by 5
Pathogenesis of Antiphospholipid Antibody Syndrome
Giles, I., Cohen, H., & Ioannou, Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47927-1.00024-4 · Cited by 5
Wang, G., Zhong, C., Peng, H. Y., Bu, X., Wang, A., Xu, T., Peng, Y., Xu, T., Li, Q., Ju, Z., et al. (2019) · Cerebrovascular Diseases · doi:10.1159/000501957 · Cited by 5
Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis
Willis, R., Cohen, H., Giles, I., Knight, J. S., Krilis, S. A., Rahman, A., & de Groot, P. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-55442-6_5 · Cited by 6
Abe, N., & ATSUMI, T. (2018) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.29.294 · Cited by 5
Taghavi, M., Lengelé, A., Laureys, M., Jacobs, L., Kaysi, S., Collart, F., Demulder, A., & Nortier, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1497810 · Cited by 4
Mammalian target of rapamycin is activated in the kidneys of patients with scleroderma renal crisis
Salituri, J., Patey, N., Takano, T., Fiset, P., Rincon, S. V. D., Berkson, L., Baron, M. G., Hudson, M., Baron, M. G., Hudson, M., et al. (2019) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198319885488 · Cited by 4
Pongphitcha, P., Okuno, Y., Vilaiyuk, S., Tunlayadechanont, P., Sasanakul, W., Kadegasem, P., Songdej, D., & Sirachainan, N. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.11.002 · Cited by 4
Pathogenesis of Antiphospholipid Syndrome
Amengual, O., & Atsumi, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801917-7.00056-5 · Cited by 4
Поражение почек на фоне антифосфолипидного синдрома
Golovach, I. Y., Yehudіna, Y. D., & Рекалов, Д. Г. (2019) · KIDNEYS · doi:10.22141/2307-1257.8.3.2019.176455 · Cited by 4
“Аналогичным образом лечение сиролимусом ассоци ировалось с резким снижением пролиферации сосудистых клеток, ингибированием развития хронических поражений (таких как фиброзная гиперплазия интимы) и более длительным сохранением функции почек [30].”
InfluentialRovin, B. H., Caster, D. J., Cattran, D. C., Gibson, K. L., Hogan, J. J., Moeller, M. J., Roccatello, D., Cheung, M., Wheeler, D. C., Winkelmayer, W. C., et al. (2021) · Nephrology (Saint-Petersburg) · doi:10.36485/1561-6274-2021-25-1-96-119 · Cited by 4
Mécanismes physiopathologiques du lupus systémique
Mathian, A., Dorgham, K., Gorochov, G., & Amoura, Z. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.10.006 · Cited by 4
“Elle est secondaire à des phénomènes thrombotiques ou à l’activation des cellules vasculaires par les polynucléaires neutrophiles, les Ac anti-phospholipides ou d’autres Ac et médiateurs inflammatoires solubles (complément et IFN par exemple) [19-21].”
BackgroundTreatment of Non-criteria Manifestations in Antiphospholipid Syndrome
Lopes, M. R. U., Criado, P. R., Parsi, K., Küçükkaya, R. D., Amigo, M., Tektonidou, M. G., & Andrade, D. C. O. (2017) · Springer eBooks · doi:10.1007/978-3-319-55442-6_13 · Cited by 4
Natural supplements in antiphospholipid syndrome: A case for further study
Kello, N., & Cho, Y. M. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109848 · Cited by 5
Zhou, X.-J., Chen, M., Wang, S.-X., Zhou, F.-D., & Zhao, M.-H. (2016) · Lupus · doi:10.1177/0961203316682098 · Cited by 4
Antiphospholipid Syndrome and the Kidney
Taghavi, M., Jacobs, L., Roccatello, D., & Sciascia, S. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.09.010 · Cited by 3
“74 Canaud et al. 75 reported that LA positivity was associated with high rates of poor transplantation outcomes during the first year after transplantation.”
InfluentialLupus nephritis and thrombotic microangiopathy: A review
Bobrova, L., & Kozlovskaya, N. L. (2024) · Terapevticheskii arkhiv · doi:10.26442/00403660.2024.06.202731 · Cited by 3
Giudice, C. D., Mahé, G., Thony, F., Zuily, S., Goyault, G., Diard, A., Loffroy, R., Galanaud, J. ‐., Thouveny, F., Quéré, I., et al. (2024) · JMV-Journal de Médecine Vasculaire · doi:10.1016/j.jdmv.2024.06.002 · Cited by 3
Inhibiting Tyrosine Kinase 2 Ameliorates Antiphospholipid Syndrome Nephropathy
Tang, K., Chen, Y.-S., Chen, T., Chao, Y., Kung, S.-P., Chen, D., & Lin, C. (2024) · Mediators of Inflammation · doi:10.1155/mi/5568822 · Cited by 3
Gao, J., Song, X., Chen, J., Liu, X.-H., & Liu, H. (2025) · Human Immunology · doi:10.1016/j.humimm.2025.111563 · Cited by 3
Endothelial dysfunction in APS: advancing pathophysiological understanding to improve management
Pericleous, C., Strauss, E., & Arachchillage, D. J. (2026) · Current Opinion in Immunology · doi:10.1016/j.coi.2026.102745 · Cited by 3
What is the best strategy in treating catastrophic antiphospholipid syndrome?
Rodríguez‐Pintó, I., Santacreu, I., Cervera, R., & Espinosa, G. (2015) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.15.25 · Cited by 3
Effects of antibodies against human parvovirus B19 on angiogenic signaling
Su, C., Hsu, T., Hsiao, C., Chiu, C., & Tzang, B. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.10921 · Cited by 3
Metabolic control of pathogenesis in autoimmune diseases
Perl, A., & Morel, L. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00059-x · Cited by 4
Antiphospholipid Syndrome: What Should Patients Know?
Erkan, D., Ünlü, O., Lally, L., & Lockshin, M. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-55442-6_19 · Cited by 3
Treatment of Systemic Lupus Erythematosus
Bertsias, G. K., Fanouriakis, A., & Boumpas, D. T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00081-4 · Cited by 4
A glimpse into the history of description of the antiphospholipid syndrome
Nour‐Eldine, W., Noureldine, H. A., Haydar, B. A., Eldine, M. N., Noureldine, M. H. A., & Uthman, I. W. (2020) · Lupus · doi:10.1177/0961203320947152 · Cited by 3
“It is also suggested that sirolimus is more important than calcineurin inhibitors for it prevents the development of vascular lesions.(81) Targeted intracellular mediators include mitogenactivated protein (MAP) kinase and nuclear factor jB (NFjB).”
BackgroundPathogenesis of antiphospholipid syndrome
Amengual, O., & Atsumi, T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814551-7.00058-1 · Cited by 3
Frederick, R., Zolio, L., Romas, E., & Ierino, F. L. (2024) · BMJ Case Reports · doi:10.1136/bcr-2022-254449 · Cited by 4
Roles of Mechanistic Target of Rapamycin in the Adaptive and Innate Immune Systems
Kato, H., & Perl, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00024-4 · Cited by 5
Purohit, A. H. L., & Kumar, M. (2019) · Springer eBooks · doi:10.1007/978-981-13-7713-6_20 · Cited by 3
Mora-Ramírez, M., González‐Pacheco, H., & Amezcua-Guerra, L. M. (2017) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000651 · Cited by 3
“In contrast, we currently do not have any effective therapy to decrease the levels of circulating aPL antibodies, and although long-term anticoagulation is the only strategy useful to reduce the recurrence of vascular thrombosis in the context of APS, it does not prevent the progression of APS-associated vasculopathy.…”
BackgroundImmunomodulatory Drugs and Monoclonal Antibodies
Liebman, H. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-68038-5_7 · Cited by 3
Nobata, H., Katsuno, T., Kachi, A., Kinashi, H., Banno, S., & Ito, Y. (2019) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001173 · Cited by 3
“Unauthorized reproduction o intrarenal vascular in patients with APS nephropathy showed indications of activation of the mammalian target of rapamycin (mTOR) complex pathway.(9) mTOR is a kinase that integrates signaling pathways to regulate cellular growth, proliferation, and survival.”
BackgroundAntiphospholipid Antibodies and Syndrome
Cervera, R. (2018) · MDPI eBooks · doi:10.3390/books978-3-03842-948-7 · Cited by 3
Siddique, F., Patel, D. P., & Roberts, W. N. (2016) · Compendium of Inflammatory Diseases · doi:10.1007/978-3-7643-8550-7_161 · Cited by 3
Yazıcı, H., & Yazıcı, Y. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000242 · Cited by 3
“51–59) further says that patients with aPL, especially the chronic and the severe forms, can present with a vasculopathy, whereas the recent interest in modalities other than simple anticoagulation in managing aPL [15,16] is probably more evidence of the complexity of this interphase.”
BackgroundWhat are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome?
Ruiz‐Irastorza, G., & Khamashta, M. A. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2090338 · Cited by 3
“The option of inhibiting the mammalian target of rapamycin complex (mTORC) with drugs such as sirolimus looks promising [4], particularly for patients with nonthrombotic aPL-related vasculopathy (like APS nephropathy), in which this pathway may play a prominent role [4,28].”
BackgroundWhy do patients with antiphospholipid syndrome bleed? A clinical paradox
Fuentes-Lacouture, M. C., Gómez, L. B., Torres, N., & Arteaga-Unigarro, C. (2023) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000001083 · Cited by 2
Kovács, A. L., Gyömörei, C., Horváth, S., Németh, V., Dudley, R., Nagy, Z., Berki, T., Lengyel, Z., & Gyulai, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062750 · Cited by 2
“Recent findings suggest that the mTOR signaling pathway may be involved in the vascular lesions associated with antiphospholipid syndrome, as aPLs bind to renal vascular endothelial cells and activate the mTOR complex [12,13].”
Huang, C. L., Zhao, Y., Jiang, H., Zhou, Y., Hu, C., Guo, X., Li, M., Zeng, X., & Zhao, J. (2025) · Clinical Rheumatology · doi:10.1007/s10067-025-07624-4 · Cited by 2
“…aPLs can activate the mTOR pathway in endothelial cells and vascular smooth muscle cells, promote cell proliferation, and lead to vascular lesions [15]. aPLs can activate platelets, the complement system, endothelial cells, and immune cells to promote coagulation and inflammation, leading to…”
Zhang, L., Dong, T., Ji, X., Chen, P., & Wang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1663849 · Cited by 2
Complement involvement in antiphospholipid syndrome
Hamidi, H., Darnige, L., & Dragon‐Durey, M. (2026) · Immunology Letters · doi:10.1016/j.imlet.2026.107148 · Cited by 2
Self-citationaPLs seroconversion in antiphospholipid syndrome: from definition to clinical relevance
Giorgio, A. D., Carnuccio, C., Nesci, A., Stefano, V. D., & Santoliquido, A. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109622 · Cited by 3
Comprehensive Review of Antiphospholipid Syndrome: Over Four Decades of Advances and Challenges
Koike, T. (2026) · Cells · doi:10.3390/cells15040356 · Cited by 2
“…cells, Canaud et al. showed that APS patients exhibited mTOR pathway activation (evidenced by S6 and Akt-S473 phosphorylation), and rapamycin treatment in transplant recipients prevented mTOR activation and reduced endothelial hyperplasia [73], suggesting mTOR inhibition as a therapeutic approach.”
Sevim, E., Erton, Z. B., & Erkan, D. (2026) · Current Opinion in Immunology · doi:10.1016/j.coi.2026.102770 · Cited by 3
Catastrophic antiphospholipid syndrome: A prototype of autoimmune thromboinflammation
Nasonov, E. L., Reshetnyak, T. M., Клименко, А. А., & Nikolaeva, E. V. (2026) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2026-227-248 · Cited by 2
Louis, K., Loupy, A., & Lefaucheur, C. (2022) · Kidney International · doi:10.1016/j.kint.2021.12.008 · Cited by 2
Ruzdija, D., Bertolo, A. J., Pandya, S., & Amaraneni, A. (2023) · Cureus · doi:10.7759/cureus.47267 · Cited by 2
Muscente, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-73467-0_13 · Cited by 2
Huo, R., Wei, C., Yang, Y., Yang, Y., Huo, X., Wang, B., Meng, D., Huang, Y., Huang, R., Lin, J., et al. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13670 · Cited by 2
“(100).”
InfluentialCostedoat-Chalumeau, N., & Morel, N. (2019) · EMC - Aparato Locomotor · doi:10.1016/s1286-935x(19)42133-3 · Cited by 3
Canaud, G. (2015) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2015.02.006 · Cited by 2
Self-citationmTORC is a potential therapeutic target in APS
Duarte, J. H. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.134 · Cited by 2
Fogo, A. B., & Kashgarian, M. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-39053-8.00004-6 · Cited by 2
Ocampo, C. R., Gutiérrez, L. A., Padilla, L. M. R., Navas, M. A. M., Franco, C. J. V., Gutiérrez-Marín, J. H., & Campo, M. N. C. (2020) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2020.01.002 · Cited by 2
“Insuficiencia placentaria 2 (11,8) 2 (22,2) 0 (0,0) Rompimiento prematuro de membranas 4 (23,5) 4 (44,4) 0 (0,0) Preeclampsia 2 (11,8) 2 (22,2) 0 (0,0) Restricción de crecimiento intrauterino 1 (5,9) 1 (11,1) 0 (0,0) Parto pretérmino 5 (29,4) 4 (44,4) 1 (12,5) Complicaciones intraparto 1 (5,9) 1 (11,1) 0 (0,0) Complic…”
Sangle, S. R., Jan, W., Matar, H. E., Rankin, S., & D’Cruz, D. P. (2021) · Rheumatology · doi:10.1093/rheumatology/keab400 · Cited by 2
Metabolic and mitochondrial dysfunction in SLE
Perl, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820583-9.00014-2 · Cited by 2
Siddique, F., Patel, D. P., & Roberts, W. N. (2015) · Encyclopedia of Inflammatory Diseases · doi:10.1007/978-3-0348-0620-6_161-6 · Cited by 2
Shovman, O., & Shoenfeld, Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00032-4 · Cited by 1
Gao, Y., Mi, L., & Xu, K. (2025) · Inflammation Research · doi:10.1007/s00011-025-02061-0 · Cited by 2
“Its cleavage product, C5a, contributes to vascular inflammation and, through interaction with C5aR, promotes endothelial cell activation, recruitment of neutrophils and monocytes, tissue factor expression, and platelet aggregation, all of which facilitate thrombus formation [80, 81].”
Tektonidou, M. G., Cervera, R., Tincani, A., Pons‐Estel, G., Sciascia, S., Stamm, T., Landewé, R., & Ward, M. M. (2025) · EULAR Rheumatology Open · doi:10.1016/j.ero.2025.07.009 · Cited by 2
“Aug-menting evidence revealed in fl ammatory, in addition to classic thrombotic, pathways in APS [24 − 30], pointing to potential new treatment targets [31 − 37].”
Rao, L., Jia, L., Li, H., Xu, L., Yang, D., Han, W., & Chen, L. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1660134 · Cited by 1
“Additionally, the formation of neutrophil extracellular traps (6), release of interleukin-8 (7), upregulation of the target of rapamycin complex on endothelial cells (8), and an imbalance in angiogenic factors (9) do not culminate in thrombosis.”
Abbas, K., Naqvi, R., Musharraf, W., Mubarak, M., & Langhani, J. L. (2025) · World Journal of Nephrology · doi:10.5527/wjn.v14.i4.110882 · Cited by 1
mTOR Signaling Pathway in Antiphospholipid Syndrome: Pathogenesis and Potential Therapeutic Targets
Huo, R., Chengcheng, W. E. I., Yang, Y., Meng, D., Yang, Y., & Huang, X. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s591631 · Cited by 1
Lupus nephritis and kidney transplantation: A narrative review of patient and graft outcomes
Elahi, T., Ahmed, S., & Mubarak, M. (2026) · World Journal of Nephrology · doi:10.5527/wjn.v15.i2.117073 · Cited by 1
Sun, C., Wan, L., Gao, H., Ding, Y., Qu, Z., & Yu, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1791188 · Cited by 1
“…patients with active systemic lupus erythematosus demonstrated only modest efficacy (Lai et al., 2018), whereas studies that stratified patients by mTORC1 activation status—either in renal tissue or functional assays—observed substantial clinical improvement (Canaud et al., 2014; Gao et al., 2023).”
Influential
Metadata
- Authors
- Canaud, G., Bienaimé, F., Tabarin, F., Bataillon, G., Seilhean, D., Noël, L.-H., Dragon-Durey, M.-A., Snanoudj, R., Friedlander, G., Halbwachs-Mecarelli, L., Legendre, C., & Terzi, F.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Inserm (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-24
- Volume
- 371
- Issue
- 4
- Pages
- 303-312
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2151319957
- Cited by
- 355
- References
- 38
- Citations by year
- 2026: 20 · 2025: 20 · 2024: 34 · 2023: 29 · 2022: 22 · 2021: 26 · 2020: 26 · 2019: 35 · 2018: 44 · 2017: 33 · 2016: 34 · 2015: 25 · 2014: 7
- FWCI
- 27.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- antiphospholipid syndrome, rapamycin, antiphospholipid antibodies, PI3K/Akt signaling, vascular endothelial cell proliferation, kidney transplantation, catastrophic antiphospholipid syndrome, renal allograft survival, vascular lesions
- MeSH terms
- Adult, Analysis of Variance, Autopsy, Endothelium, Vascular, Female, Humans, Immunoglobulin G, Immunosuppressive Agents, Kidney, Kidney Diseases, Male, Middle Aged, Kidney Transplantation, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Sirolimus, Cell Proliferation, Metabolic Networks and Pathways, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.